MCUJ.F Stock Overview
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.80 |
| 52 Week High | CA$1.26 |
| 52 Week Low | CA$0.68 |
| Beta | 1 |
| 1 Month Change | -8.91% |
| 3 Month Change | -20.11% |
| 1 Year Change | -16.89% |
| 3 Year Change | -40.38% |
| 5 Year Change | -82.97% |
| Change since IPO | -96.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| MCUJ.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | 1.0% | 1.2% |
| 1Y | -16.9% | 0.7% | 24.9% |
Price Volatility
| MCUJ.F volatility | |
|---|---|
| MCUJ.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MCUJ.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MCUJ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| MCUJ.F fundamental statistics | |
|---|---|
| Market cap | US$7.54m |
| Earnings (TTM) | -US$672.95k |
| Revenue (TTM) | US$15.83m |
0.5x
P/S Ratio-12.3x
P/E RatioIs MCUJ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCUJ.F income statement (TTM) | |
|---|---|
| Revenue | CA$21.69m |
| Cost of Revenue | CA$7.71m |
| Gross Profit | CA$13.99m |
| Other Expenses | CA$14.91m |
| Earnings | -CA$922.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | 64.48% |
| Net Profit Margin | -4.25% |
| Debt/Equity Ratio | 0% |
How did MCUJ.F perform over the long term?
See historical performance and comparison